Effect of Dapagliflozin combined with insulin treatment on blood glucose index and pancreatic β-cell function in overweight/obese type 2 diabetes mellitus patients with different disease durations
10.3969/j.issn.1006-6187.2024.12.004
- VernacularTitle:达格列净联合胰岛素治疗对不同糖尿病病程的超重/肥胖2型糖尿病患者血糖指数和胰岛β细胞功能影响的研究
- Author:
Yan ZHANG
1
;
Yuli LU
1
;
Miao MIAO
1
;
Yongqi FU
1
;
Xiaolong LI
1
;
Dianjing SUN
1
;
Jianlin GENG
1
Author Information
1. 053000衡水市人民医院内分泌科
- Publication Type:Journal Article
- Keywords:
Diabetes mellitus,type 2;
Obesity;
Dapagliflozin;
Insulin;
Disease duration
- From:
Chinese Journal of Diabetes
2024;32(12):898-902
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effects of Dapagliflozin combined with insulin treatment on blood glucose index and pancreatic β-cell function in overweight/obese type 2 diabetes mellitus(T2DM) patients with different disease durations. Methods A total of 288 patients with impaired pancreatic function who were treated from June 2019 to June 2020 were selected. They were divided into three groups,short duration group (≤10 years group,n=95),medium duration group (10～20 years group,n=96) and long duration group (≥20 years group,n=97). Three groups of patients were treated with Dapagliflozin in addition to the regular insulin therapy for 6 months. Clinical efficacy,blood glucose indices,pancreatic β-cell function and complications during the treatment period were compared among the three groups. Results After treatment,there was a significant decrease in the values of three groups including WC,FPG,2 hPG,HbA1c,TC,TG,LDL-C,BMI,FIns and HOMA-IR(P<0.05). Meanwhile,HDL-C,C-P,HOMA-β and HOMA-IS values showed a significant increase(P<0.05). After treatment,WC,FPG,2 hPG,HbA1c,TC,TG,LDL-C,FIns and HOMA-IR increased in turn(P<0.05),while HDL-C,C-P,HOMA-β and HOMA-IS decreased in turn in ≤10 years group,10～20 years group,≥20 years group(P<0.05). The BMI of 10～20 years group was lower than that of ≤10 years group and ≥20 years group (P<0.05),while the BMI of ≥20 years group was higher than that of ≤10 years group (P<0.05). Conclusions In overweight/obese T2DM patients with different DM durations,Dapagliflozin combined with insulin treatment shows a significant advantage in lowering blood glucose indices and improving pancreatic β-cell function,especially for patients with a shorter disease duration.
